Mergers & Acquisitions
By The Online Investor Staff, updated Wed., Feb. 26, 5:45 PM
Slide #94. Foamix Pharmaceuticals Ltd — Menlo Therapeutics Inc.
| Acquirer: |
Foamix Pharmaceuticals Ltd (FOMX) |
| Acquiree: |
Menlo Therapeutics Inc. (MNLO) |
| Details: |
Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX ) and Menlo Therapeutics Inc. (Nasdaq: MNLO) today announced that the shareholders of Foamix and stockholders of Menlo voted to approve all shareholder and stockholder proposals necessary to complete the previously announced merger at their respective shareholder / stockholder meetings held earlier today. Pending the expiration of a 30-day waiting period required by Israeli law and satisfaction of closing conditions set forth in the merger agreement between Foamix, Menlo and Giants Merger Subsidiary Ltd., a wholly-owned subsidiary of Menlo, Menlo's merger subsidiary will merge with and into Foamix, with Foamix surviving as a wholly-owned subsidiary of Menlo. |
Foamix Pharmaceuticals is a clinical-stage specialty pharmaceutical company focused on developing and commercializing Co.'s proprietary topical drug candidates for dermatological therapy. Co.'s main product candidate, FMX101 (4% minocycline foam), is being developed for the treatment of moderate-to-severe acne and its second product candidate, FMX103 (1.5% minocycline foam), is being developed for the treatment of moderate-to-severe papulopustular rosacea. Both product candidates are topical foam formulations of the antibiotic minocycline and were developed using its Molecule Stabilizing Technology, a proprietary foam platform designed to optimize the topical delivery of minocycline.
Open the FOMX Page at The Online Investor »
Foamix Pharmaceuticals is a clinical-stage specialty pharmaceutical company focused on developing and commercializing Co.'s proprietary topical drug candidates for dermatological therapy. Co.'s main product candidate, FMX101 (4% minocycline foam), is being developed for the treatment of moderate-to-severe acne and its second product candidate, FMX103 (1.5% minocycline foam), is being developed for the treatment of moderate-to-severe papulopustular rosacea. Both product candidates are topical foam formulations of the antibiotic minocycline and were developed using its Molecule Stabilizing Technology, a proprietary foam platform designed to optimize the topical delivery of minocycline.
Open the MNLO Page at The Online Investor »
| Company Name: |
| Foamix Pharmaceuticals Ltd. |
| Website: |
| www.foamix.co.il |
| Sector: |
| Drugs & Pharmaceuticals |
| Number of ETFs Holding FOMX: |
| 4 |
| Total Market Value Held by ETFs: |
| $2.17M |
| Total Market Capitalization: |
| $247.00M |
| % of Market Cap. Held by ETFs: |
| 0.88% |
|
| Company Name: |
| Menlo Therapeutics Inc |
| Website: |
| www.menlotherapeutics.com |
| Sector: |
| Drugs & Pharmaceuticals |
| Number of ETFs Holding MNLO: |
| 12 |
| Total Market Value Held by ETFs: |
| $3.49M |
| Total Market Capitalization: |
| $119.00M |
| % of Market Cap. Held by ETFs: |
| 2.93% |
|
Quotes delayed 20 minutes
|
